NMTC
NeuroOne Medical Technologies Corporation0.7068
+0.0458+6.93%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q1 '26
Q&A reaffirms, trigeminal color added
Q&A largely reaffirmed prepared remarks, offering color on trigeminal neuralgia without contradictions or new guidance. All nine patients across three centers—including late Dr. Grewal's—reported pain-free outcomes, highlighting the probe's single-placement advantage. OpEx should hold SG&A flat while R&D fluctuates with drug delivery acceleration and upcoming animal studies. Feedback praises seizure reductions, bedside ablations, and ease of use. Zimmer bears all marketing costs. Details stayed thin on Zimmer's center count or regional traction. Management tone stayed upbeat; investors eye strategic diligence closes.
Key Stats
Market Cap
35.34MP/E (TTM)
-Basic EPS (TTM)
-0.16Dividend Yield
0%Recent Filings
10-Q
Q1 FY2026 results
NeuroOne's product revenue dipped 12% y/y to $2.9M for Q1 FY2026 ended December 31, 2025, with gross margin contracting to 54.2% from 58.9% on higher direct sales mix and material costs, while operating expenses held steady but R&D rose 19% y/y on drug delivery work. No license revenue this quarter after $3M Zimmer upfront last year; net loss hit $1.4M versus $1.8M profit, driven by absent licensing and financing gains. Cash burned $3.1M in operations (FCF not disclosed in the 10-Q), ending at $3.6M with no debt after terminating the facility. Warrant exercises added $0.2M. Zimmer amended minimum purchase terms December 31. Single customer took 100% revenue. Cash runway tightens.
8-K
Q1 revenue dips, FY guide up
NeuroOne reported Q1 fiscal 2026 product revenue of $2.9 million, down slightly from $3.3 million a year ago due to a one-time Zimmer stocking order, yet up 5.5% sequentially. OneRF ablation system saw nearly 50% of all ablations since 2024 launch in this quarter alone. Cash stands at $3.6 million; full-year product revenue guidance is at least $10.5 million.
8-K
Mills joins NeuroOne board
NeuroOne expanded its board to five members and appointed Jason R. Mills, Penumbra's EVP of Strategy and veteran med-tech analyst, as Class I director effective December 18, 2025. Mills joins Compensation and Nominating committees January 1, 2026, bringing capital markets savvy. Veteran hire bolsters strategy. Updated deck posted December 22.
8-K
Revenue up 163% to $9.1M
NeuroOne crushed fiscal 2025 with product revenue soaring 163% to $9.1 million and Q4 exploding 907% to $2.7 million, driven by OneRF Ablation System sales. Gross margins jumped to 56.5% while operating expenses fell 4.6% to $12.4 million; net loss shrank 71% to $3.6 million. Cash hit $6.6 million, funding through 2026. FDA-cleared Trigeminal system treated first patients successfully.
BWAY
Brainsway Ltd.
16.87-0.47
CBLL
CeriBell, Inc.
21.99+0.09
CLPT
ClearPoint Neuro Inc.
13.82+1.44
HSDT
Solana Company
3.10+0.06
INSP
Inspire Medical Systems, Inc.
115.51-3.75
MDT
Medtronic plc.
97.72-0.85
NPCE
Neuropace, Inc.
15.88-0.04
NXL
Nexalin Technology, Inc.
0.81-0.01
STIM
Neuronetics, Inc.
1.65-0.11
VYCO
Vycor Medical, Inc.
0.16+0.00